Eagle Financial Statements From 2010 to 2024

EGRX Stock  USD 4.55  0.22  4.61%   
Eagle Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Eagle Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Eagle Pharmaceuticals financial statements helps investors assess Eagle Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Eagle Pharmaceuticals' valuation are summarized below:
Gross Profit
221.7 M
Profit Margin
0.0464
Market Capitalization
61.8 M
Enterprise Value Revenue
0.4494
Revenue
257.6 M
We have found one hundred twenty available fundamental signals for Eagle Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Eagle Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 500.4 M in 2024. Enterprise Value is likely to rise to about 466.6 M in 2024

Eagle Pharmaceuticals Total Revenue

382.31 Million

Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many exotic indicators such as Price To Sales Ratio of 1.3, Ptb Ratio of 1.77 or Days Sales Outstanding of 129. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Eagle Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Eagle Pharmaceuticals Technical models . Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

Eagle Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets490.4 M467.1 M204.8 M
Slightly volatile
Short and Long Term Debt Total41.6 M71.8 M39.1 M
Slightly volatile
Other Current Liabilities103.7 M98.7 M24.8 M
Slightly volatile
Total Current Liabilities134.1 M127.8 M52.2 M
Slightly volatile
Property Plant And Equipment Net2.3 M1.3 M1.8 M
Slightly volatile
Current Deferred Revenue17.3 M29.2 M16.5 M
Slightly volatile
Accounts Payable22.9 M21.8 M9.5 M
Slightly volatile
Cash73 M63.6 M58.4 M
Slightly volatile
Non Current Assets Total262.5 M250 M82.6 M
Slightly volatile
Non Currrent Assets Other19 M18.1 M4.5 M
Slightly volatile
Other Assets63.9 M60.8 M20.6 M
Slightly volatile
Cash And Short Term Investments75.1 M63.6 M60.2 M
Slightly volatile
Net Receivables87.5 M83.3 M39.3 M
Slightly volatile
Common Stock Total Equity15.2 K20.7 K12.7 K
Slightly volatile
Common Stock Shares Outstanding14.9 M15 M13.3 M
Slightly volatile
Liabilities And Stockholders Equity490.4 M467.1 M204.8 M
Slightly volatile
Non Current Liabilities Total74.3 M70.7 M26.9 M
Slightly volatile
Inventory57.7 M55 M15.4 M
Slightly volatile
Other Current Assets8.2 M15.2 M7.1 M
Slightly volatile
Other Stockholder Equity100.8 M110.8 M117.7 M
Very volatile
Total Liabilities208.4 M198.5 M77.7 M
Slightly volatile
Property Plant And Equipment Gross9.4 M8.9 M3.7 M
Slightly volatile
Total Current Assets137 M217.1 M116.1 M
Slightly volatile
Common Stock15.2 K20.7 K12.7 K
Slightly volatile
Property Plant Equipment2.3 M1.3 M1.8 M
Slightly volatile
Other Liabilities3.2 M3.4 M11.9 M
Slightly volatile
Net Tangible Assets106.8 M80.7 M79.6 M
Slightly volatile
Capital Surpluse282.9 M421.2 M237.9 M
Slightly volatile
Non Current Liabilities Other5.1 M4.8 M12.2 M
Slightly volatile
Long Term Debt Total43.1 M64.6 M44 M
Slightly volatile
Net Invested Capital250.6 M340.4 M236.4 M
Slightly volatile
Short and Long Term Debt10.3 M7.2 M7.2 M
Slightly volatile
Net Working Capital94.7 M69.9 M124.3 M
Slightly volatile
Capital Stock18.9 K20.7 K17.4 K
Slightly volatile
Capital Lease Obligations4.5 M6.1 M3.6 M
Slightly volatile

Eagle Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization14.5 M13.8 M4.4 M
Slightly volatile
Interest Expense4.9 M4.7 M1.8 M
Slightly volatile
Selling General Administrative118.5 M112.8 M55.6 M
Slightly volatile
Total Revenue382.3 M364.1 M157.6 M
Slightly volatile
Other Operating Expenses284.5 M271 M129.7 M
Slightly volatile
Research Development32.8 M39.2 M28.3 M
Slightly volatile
Cost Of Revenue114.6 M109.2 M45.7 M
Slightly volatile
Total Operating Expenses89 M161.8 M78.6 M
Slightly volatile
Preferred Stock And Other Adjustments1.3 M1.5 M1.6 M
Slightly volatile
Interest Income537.5 K311.6 K321.9 K
Slightly volatile
Non Recurring13.7 M8.5 M13.6 M
Pretty Stable
Selling And Marketing Expenses5.2 M9.8 M3.5 M
Slightly volatile
Reconciled Depreciation14.5 M13.8 M5.8 M
Slightly volatile

Eagle Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation13.2 M18.9 M11 M
Slightly volatile
Begin Period Cash Flow69.4 M112.3 M59.5 M
Slightly volatile
Depreciation14.5 M13.8 M4.2 M
Slightly volatile
Capital Expenditures152.2 K160.2 KM
Very volatile
End Period Cash Flow73 M63.6 M58.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.31.3712.8104
Slightly volatile
Days Sales Outstanding12996.04126
Slightly volatile
Stock Based Compensation To Revenue0.06480.04680.0815
Pretty Stable
EV To Sales1.331.412.5867
Slightly volatile
Inventory Turnover2.172.2810.0032
Slightly volatile
Days Of Inventory On Hand174165118
Pretty Stable
Payables Turnover4.074.54.714
Slightly volatile
Sales General And Administrative To Revenue0.290.280.3265
Pretty Stable
Research And Ddevelopement To Revenue0.120.10770.9352
Slightly volatile
Cash Per Share4.023.854.5911
Slightly volatile
Days Payables Outstanding97.4283.9894.2694
Slightly volatile
Intangibles To Total Assets0.210.360.2963
Slightly volatile
Current Ratio2.31.532.6319
Slightly volatile
Receivables Turnover2.753.933.2409
Slightly volatile
Graham Number31.6230.1217.8054
Slightly volatile
Revenue Per Share23.1322.0311.0433
Slightly volatile
Dividend Yield0.00290.00420.0016
Slightly volatile
Average Inventory783.1 K881 K959.3 K
Slightly volatile
Average Receivables2.7 MM3.3 M
Slightly volatile
Days Of Payables Outstanding97.4283.9894.2694
Slightly volatile
Ebt Per Ebit0.831.031.0192
Pretty Stable
Long Term Debt To Capitalization0.170.220.1754
Slightly volatile
Quick Ratio2.021.042.2881
Pretty Stable
Net Income Per E B T1.060.670.9523
Very volatile
Cash Ratio0.430.451.3933
Very volatile
Days Of Inventory Outstanding174165118
Pretty Stable
Days Of Sales Outstanding12996.04126
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.071.151.0065
Very volatile
Fixed Asset Turnover25624493.0723
Slightly volatile
Price Sales Ratio1.31.3712.8104
Slightly volatile
Asset Turnover0.550.70.6393
Slightly volatile
Operating Cycle236307242
Very volatile
Cash Conversion Cycle101175142
Very volatile

Eagle Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap500.4 M340.3 M613.9 M
Pretty Stable
Enterprise Value466.6 M346.7 M576.1 M
Pretty Stable

Eagle Fundamental Market Drivers

Forward Price Earnings11.3379
Cash And Short Term Investments55.3 M

Eagle Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

About Eagle Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Eagle Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Eagle Pharmaceuticals investors use historical funamental indicators, such as Eagle Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Eagle Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Eagle Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eagle Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eagle Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue29.2 M17.3 M
Total Revenue364.1 M382.3 M
Cost Of Revenue109.2 M114.6 M
Stock Based Compensation To Revenue 0.05  0.06 
Sales General And Administrative To Revenue 0.28  0.29 
Research And Ddevelopement To Revenue 0.11  0.12 
Capex To Revenue(0.0005)(0.0005)
Revenue Per Share 22.03  23.13 
Ebit Per Revenue 0.15  0.16 

Pair Trading with Eagle Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eagle Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eagle Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Eagle Stock

  0.73ACB Aurora Cannabis TrendingPairCorr
  0.7CGC Canopy Growth Corp TrendingPairCorr
  0.5ELYM Eliem TherapeuticsPairCorr
  0.49XFOR X4 Pharmaceuticals Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Eagle Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eagle Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eagle Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eagle Pharmaceuticals to buy it.
The correlation of Eagle Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eagle Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eagle Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eagle Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:
Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Commodity Directory
Find actively traded commodities issued by global exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.87)
Earnings Share
0.85
Revenue Per Share
19.684
Quarterly Revenue Growth
(0.13)
Return On Assets
0.0663
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.